Pharmacy Tirzepatide

Tirzepatide Dosage and Titration Schedule — Pharmacy Tirzepatide

The short version

Tirzepatide dosage in the clinical trial programme: once-weekly subcutaneous injection, starting at 2.5 mg and increasing by 2.5 mg every four weeks — to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and up to 15 mg. The starting dose is too low to produce much weight or glucose effect; its purpose is tolerability. The therapeutic doses studied across the SURPASS and SURMOUNT trials were 5 mg, 10 mg, and 15 mg as maintenance doses. The half-life is approximately five days, which is why weekly dosing keeps blood levels stable. This page documents the dosage and pharmacokinetics from the published trial record and the FDA prescribing label. This site does not provide personal dosing advice.

Tirzepatide dosage: the FDA-labeled and trial-documented schedule

The tirzepatide dosage and titration schedule used across the SURPASS and SURMOUNT phase 3 programmes, and documented in the FDA prescribing information, is as follows [7]:

Tirzepatide injection titration ladder (subcutaneous, once weekly):

  • 2.5 mg: weeks 1–4 (initiation dose for tolerability; not a therapeutic maintenance dose)
  • 5 mg: weeks 5–8 (first maintenance dose; primary SURPASS/SURMOUNT evaluation point)
  • 7.5 mg: weeks 9–12 (if tolerated and additional glycaemic control or weight reduction needed)
  • 10 mg: weeks 13–16
  • 12.5 mg: weeks 17–20
  • 15 mg: week 20 onward (maximum dose; not all participants reach or tolerate this)

In the SURPASS-2 trial (40 weeks), the three maintenance doses were 5, 10, and 15 mg — all demonstrated noninferior and superior HbA1c reductions versus the comparator [3]. In SURMOUNT-1 (72 weeks), the same three maintenance doses were used, with the 15 mg arm achieving the largest weight reduction (−20.9%) [4]. In SURMOUNT-5, participants were randomised to tirzepatide's maximum tolerated dose, with most reaching 15 mg [5].

The starting dose of 2.5 mg was selected specifically to minimise early gastrointestinal side effects during the initiation period. The dose-escalation interval of four weeks was designed to allow tolerability adaptation before advancing.

Tirzepatide dose: pharmacokinetics and half-life

Tirzepatide's pharmacokinetics were characterised in the phase 1 programme (Urva S, et al., Diabetes Obes Metab, 2020) and supported once-weekly dosing on the basis of the following parameters [13]:

  • Elimination half-life: approximately 5 days (range reported across studies: 4.6–5.5 days). The C20 fatty-diacid modification enables albumin binding, dramatically slowing clearance compared with the native GIP peptide.
  • Route of administration: subcutaneous injection only — this is the only route studied in the approved and clinical-trial programme. Oral bioavailability is low; no oral formulation is currently approved.
  • Time to peak concentration (Tmax): approximately 8–72 hours post-injection, with a broad peak consistent with the subcutaneous depot absorption.
  • Accumulation: once-weekly dosing produces approximately two- to threefold accumulation relative to the first dose, reaching steady state in two to four weeks.

The approximately five-day half-life means that after a missed dose, blood concentrations decline to roughly half the steady-state level within five days. Conversely, stopping the medication requires approximately four to five half-lives (approximately 25 days) before concentrations approach undetectable levels. This long tail is the mechanistic basis for the weight regain observed in discontinuation studies [30][31].

Tirzepatide injection: administration and practical notes from the trial record

The tirzepatide injection is administered subcutaneously — typically into the abdomen, thigh, or upper arm. Clinical trial protocols rotated injection sites to manage local reactions. Marketed formulations are refrigerated; the prescribing information documents specific storage requirements [7].

Dose reduction: The prescribing information permits reducing the tirzepatide dose if a patient does not tolerate an increase — for example, returning to the prior dose for an additional four weeks before re-attempting escalation [7].

Co-administration considerations: When combined with a sulfonylurea or insulin, the label advises that a lower dose of the co-administered secretagogue or insulin may be needed to reduce hypoglycaemia risk [7]. Delayed gastric emptying transiently reduces the absorption rate (not total absorption) of co-administered oral medications; the prescribing information specifically flags potential reduced reliability of oral hormonal contraceptives around the time of initial dosing and dose increases [7][13].

Duration: The SURMOUNT programme demonstrated that benefits are maintained with continued treatment, and that stopping the medication results in substantial weight regain. SURMOUNT-4 showed that participants continuing the drug kept losing weight while those switched to placebo regained [31]. This evidence underpins the framing of tirzepatide as a chronic rather than short-course treatment.

Tirzepatide cost: what the literature addresses

This site does not carry pricing information, sourcing information, or access guidance. The negative-terms policy of this site explicitly excludes cost and purchasing terms.

What the research literature does address is access in the context of clinical effectiveness: the pragmatic SURMOUNT-REAL UK trial, for example, is examining healthcare resource use and productivity outcomes alongside clinical endpoints — a recognition that real-world cost-effectiveness data is needed beyond the pivotal trial programme [38]. Payer coverage, patient assistance programmes, and formulary access are outside the scope of this research digest.